TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03194295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Support Intervention Group
Description: This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant. The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities. For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance Use Disorder Educational Group
Description: This 12-week educational group is designed as an attention-control group. Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness. Participants will be assigned 2 homework assignments each week based on the topic.
Study: NCT00560573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
Study: NCT03613207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraqix® gel
Description: Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
Study: NCT00729937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: 500 mg, four times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: 300 mg, four times per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: 4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
Study: NCT03613207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dOFM-System
Description: Dermal open flow microperfusion system will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations over 24 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 8 blood samples will be collected in order to assess systemic lidocaine/prilocaine concentrations pre-dose (1 sample) and 24 hours post dose (7 samples)
Study: NCT03112161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eucaloric Feeding Period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overfeeding Feeding Period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Underfeeding Feeding Period
Study: NCT01026870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCH 32088 mometasone furoate (MF) metered-dose inhaler
Description: 2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo metered-dose inhaler BID
Description: 2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
Study: NCT02034526

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DDDR-60
Description: DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DDD-40
Description: DDD, lower pacing rate 40 bpm, RR function off
Study: NCT01818804

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3PUFA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Study: NCT03560323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-hydroxy-butyrate
Description: Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (26 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.~GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-hydroxy-butyrate
Description: Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (26 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.~GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-hydroxy-butyrate
Description: Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (26 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.~GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end
Study: NCT04070833

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D placebo
Description: Vitamin D placebo
Study: NCT00560573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75\* mg/m2 or 80\* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.~\* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
Study: NCT04070833

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D placebo
Description: Vitamin D placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study: NCT03373175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basal record
Description: Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basal record
Description: Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basal record
Description: Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basal record
Description: Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 10 record
Description: PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 10 record
Description: PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 10 record
Description: PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 10 record
Description: PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
Study: NCT03099265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant mFOLFIRINOX
Description: Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
Study: NCT03373175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 15 record
Description: PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 15 record
Description: PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 15 record
Description: PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
Study: NCT03269565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD-1 monoclonal antibody
Study: NCT03373175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 15 record
Description: PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 20 record
Description: PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 20 record
Description: PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 20 record
Description: PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 20 record
Description: PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
Study: NCT03125369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy + duodeno-jejunal bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-Y gastric bypass
Study: NCT03863210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk
Description: All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits.
Study: NCT04379167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma. PI3K-δ signaling pathways are frequently hyperactive in B-cell cancers, making inhibition of PI3K-δ a promising target for B-cell malignancies. YY 20394 has high potency against PI3K-δ, but with markedly improved selectivity in in vitro assays compared to idelalisib. This higher selectivity for PI3K-δ may decrease the risk of serious infection seen with idelalisib and duvelisib (a PI3K-γ/δ dual inhibitor) due to strong immune suppression.
Study: NCT03512106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Chinese traditional acupuncture

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Chinese traditional acupuncture
Study: NCT05446116

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial splenic artery embolization
Description: embolization of the splenic artery for the treatment of hypersplenism

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial splenic artery embolization
Description: embolization of the splenic artery for the treatment of hypersplenism
Study: NCT01935492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
Description: 1. st line:~   * Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * Bevacizumab until PD or unacceptable toxicity~  * At PD patients will go to the 2nd treatment line.~2. nd line:~   * Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
Description: Arm B~1. st line~   * Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~  * Bevacizumab until PD or unacceptable toxicity~  * At PD \< 3 months after last paclitaxel start 2nd treatment line.~  * At PD ≥ 3 months after last paclitaxel, start another 4 cycles~  * Bevacizumab until the next PD or unacceptable toxicity~  * At the next PD start the 2nd treatment line.~2. nd line:~   * Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~  * At PD \< 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~  * At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~  * At the next PD start 3rd treatment line.
Study: NCT04279002

Intervention type: OTHER
Intervention: Brief 15-question questionnaire
Description: Questionnaire is mailed retrospectively to the respiratory rehabilitation program and aimed at targeting 17 psycho-social traits. Response time is estimated at 10 minutes
Study: NCT01339273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Transversus Abdominis Plane (TAP) bock
Description: Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anaesthetic infiltration of laparoscopic port sites
Description: Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
Study: NCT02978729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two-way videoconference remote genetic counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone remote genetic counseling
Study: NCT03076307

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Procedural Motor Skills with mirror-drawing of figures
Description: Evaluation of error rate and speed for completion of a procedural motor task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Procedural Motor Skills with mirror-drawing of figures
Description: Evaluation of error rate and speed for completion of a procedural motor task
Study: NCT01366846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avoidance of peanut
Description: All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avoidance of peanut
Description: All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
Study: NCT03752424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver nanoparticles
Description: The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical approved anti-microbial gel
Description: The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
Study: NCT00952432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Carbamazepine 200mg, 1/2 tablet, TID for 1 month

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture
Study: NCT02140801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Plain, round, yellow, filmcoated tablet, 90 mg
Study: NCT01956110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta (FE 999049)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa (GONAL-F)
Study: NCT00460941

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20mg
Description: sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20mg-30mg
Description: sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20mg-40mg
Description: sc weekly
Study: NCT03182348

Intervention type: PROCEDURE
Intervention: Optical coherence tomography
Description: As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
Study: NCT00846118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: 1-4mg/day
Study: NCT03085329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seattle-PAP
Description: Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional bubble nasal CPAP
Description: Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher \& Paykel bubbler device, which is the standard of care at Nationwide Children's.
Study: NCT00742313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FloSeal Matrix
Description: 10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.